维立志博预计将于7月25日（星期五）上午九时正开始在香港联交所主板交易，股份代号为9887，每手买卖 单位为100股股份，入场费3535.3港元。 基石投资者方面，维立志博引入了9名基石投资者，包括LVC实体、OrbiMed、高毅实体、TruMed、腾讯 (00700.HK)、易方达基金、Foresight Funds、Sage Partners、汉康实体。基石投资者累计认购总金额为6900万 美元（或约5.416亿港元）的发售股份。 维立志博是一家临床阶段生物科技公司，专注于肿瘤、自身免疫性疾病及其他重大疾病新疗法的发现、开发 及商业化。公司已建立多元化的产品组合，包括4款核心及主要产品，各款产品组合均处于全球临床进度领 先的候选药物之列。 公司的核心产品LBL-024已于2024年7月进入针对晚期肺外神经内分泌癌的单臂注册临床试验，是全球达到注 册临床试验阶段的首款4-1BB靶向候选药物。公司预期至2026年第三季度向NMPA提交LBL-024的首个生物制 品许可申请。 财华社讯，7月17日，生物科技公司维立志博(09887.HK)启动招股，计划全球发售3205.44万股股份，其中 2884.89万股股份 ...

据 IPO早知道消息， 南京维立志博生物科技股份有限公司 （以下简称 " 维立志博 "）今起招股、 至22日结束，并计划于2025年7月25日正式以"9887"为股票代码在港交所主板挂牌上市。 这意味着，维立志博即将成为 "国内TCE领域第一股"。 维立志博 在本次计划发行 32,054,400股H股 ，其中香港公开发售 3,205,500股H股 ，国际发售 28,848,900股H股 。以每股 31.60港元至35.00港元的发行区间计算， 维立志博 的 IPO市值将介 于59.58亿港元至65.99亿港元。 IPO市值将介于59.58亿港元至65.99亿港元。 本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 值得注意的是，维立志博本次总计引入 9位基石投资者，累计认购6900万美元（约5.416亿港元） ——其中，高毅、 TruMed 和 OrbiMed 分别认购 1000万美元，腾讯认购800万美元，易方达基 金认购700万美元， Foresight Funds 认购 500万美元， Sage Partners 认购 400万美元，现有 股东正心谷资本和汉康资本 ...

Q&A 联邦制药近期有哪些重要的转型和创新成果？ 联邦制药近年来积极进行转型创新，取得了显著成果。2025 年 3 月，公司与 诺和诺德达成了一项重磅授权协议，涉及其 GLP-1 注射剂 UBT 251。此外， 公司在大分子、小分子、减肥、降糖以及自免等多个领域储备了完善的创新药 管线。最近，公司第二代胃肠道激素管线 UBT 37,034（PYY 靶点）在美国获 批 IND，这一药物用于减肥和降糖，显示出较大的市场潜力。 联邦制药 20250715 摘要 联邦制药在小分子、减肥、降糖和自免等领域储备了完善的创新药管线， 第二代胃肠道激素管线 UBT 37,034（PYY 靶点）已在美国获批 IND， 用于减肥和降糖，显示出市场潜力。 联邦制药通过业务整合模式平滑原料药行业的周期性波动，并延伸至下 游制剂领域，提升整体盈利能力。公司参与国内集采，并将胰岛素等产 品出口海外，动保产能预计 2025 年落地，贡献收入增长。 2019 年至 2023 年，联邦制药收入从 84 亿元增长至 137.5 亿元，利 润从 5.3 亿元增长至 27 亿元，利润增速快于收入增速，得益于产品涨 价及高毛利率，销售费用率和管理费用 ...

Group 1 - Jichuan Pharmaceutical's "Children's Constipation Granules" has received a registration application acceptance notice, marking it as the first innovative traditional Chinese medicine specifically for treating pediatric constipation [1] - The product is expected to be the first Class 1 pediatric-specific drug for constipation following the release of the clinical research guidelines in 2024 [1] Group 2 - Innovent Biologics' drug Daberat® has become the first KRAS G12C inhibitor approved in Macau, providing a new targeted therapy for patients with advanced non-small cell lung cancer [2] - In a Phase II clinical trial, Daberat® demonstrated an objective response rate (ORR) of 49.1%, a median progression-free survival (PFS) of 9.7 months, and a 12-month overall survival (OS) rate of 54.4% [2] Group 3 - Sinovac Biotech's special shareholders meeting approved the election of 10 new directors proposed by SAIF Partners, who committed to support the company's dividend distribution plan [3] - The new board members aim to work closely with management to restore trading of the company's common stock and enhance long-term shareholder value [3] Group 4 - Ganli Pharmaceutical expects a net profit increase of 100.73% to 114.12% for the first half of 2025, with projected profits between 600 million to 640 million yuan [4] - The company achieved market share expansion through two rounds of insulin procurement, with a significant 32.6% increase in agreement volume during the 2024 procurement [4] Group 5 - Ascentage Pharma's new Bcl-2 inhibitor, Lisangtuo® (APG-2575), has been conditionally approved for marketing in China, becoming the first Bcl-2 inhibitor for chronic lymphocytic leukemia/small lymphocytic lymphoma [5] - This marks Ascentage Pharma's second innovative drug to be approved and enter the commercialization stage [5] Group 6 - United Biomedical's UBT37034 injection has received FDA approval for clinical trials, showing significant weight reduction effects when combined with GLP-1 analogs in preclinical studies [6] - The combination therapy demonstrated superior weight loss effects compared to other investigational drugs [6]

研 行 行业周报 业 半年报预告密集披露，关注业绩表现 ——医药生物行业周报 究 分析师： 侯雅楠 SAC NO： S1150524120001 2025 年 07 月 11 日 医药生物 投资要点： 证券分析师 行业要闻 侯雅楠 022-23839211 houyn@bhzq.com （1）国家医疗保障局公布《2025 年国家基本医疗保险、生育保险和工伤保 险药品目录及商业健康保险创新药品目录调整工作方案》等相关文件； 研究助理 近三月行业指数走势图 （2）默沙东 100 亿美元收购 Verona，获得慢性阻塞性肺病（COPD）重磅 新药； （3）7.2mg 司美格鲁肽申报上市。 证 公司公告 券 研 （1）亚盛医药-B：自愿公告新型 Bcl-2 抑制剂利沙托克拉（利生妥®）正式 获中国国家药品监督管理局批准，用于治疗成人慢性淋巴细胞白血病/小淋巴 细胞淋巴瘤患者； 究 （2）药明康德：2025 年半年度业绩预增公告； 报 相关研究报告 （3）甘李药业：2025 年半年度业绩预增公告； 告 录有望出台——医药生物行 （4）艾力斯：自愿披露关于甲磺酸伏美替尼片 EGFR 20 外显子插入突变 NSCLC 二线 ...

Group 1 - The National Healthcare Security Administration has released the adjustment plan for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, which includes a new commercial health insurance innovative drug catalog, potentially accelerating the commercialization of innovative drugs and enhancing investor confidence in the pharmaceutical sector [1] Group 2 - WuXi AppTec expects a net profit of approximately 8.561 billion yuan for the first half of 2025, representing a year-on-year increase of about 101.92%, driven by both core business and non-recurring gains, indicating strengthened competitiveness in the global pharmaceutical market [2] Group 3 - As the second Bcl-2 inhibitor approved globally, Ascentage Pharma's "Lisenglitazone" is expected to capture market share quickly, enhancing investor confidence and boosting the company's valuation in the innovative drug sector [3] Group 4 - Federated Pharmaceutical's innovative drug "UBT37034 injection" has received FDA approval for clinical trials targeting overweight or obesity, indicating significant market potential and enhancing the company's competitiveness in the innovative drug field [4] Group 5 - North China Pharmaceutical expects a net profit of approximately 124 million yuan for the first half of 2025, a year-on-year increase of around 72%, attributed to improved management and operational efficiency, which strengthens investor confidence in the company's future growth [5]

Major Events - QianShi International (00381) subsidiary FuLao Investment signed a memorandum of understanding with Yanji Municipal Government for potential cooperation in digital economy-related businesses in Hong Kong [1] - Stone Pharmaceutical Group (02005) obtained production registration approval for potassium chloride and sodium chloride injection (500ml and 250ml) [1] - Basilea Pharmaceutica (02616) received approval from the National Medical Products Administration for the domestic production registration application of Prujita® (Pralsetinib capsules) [1] - United BioPharma (03933) received FDA approval for new drug clinical trials for UBT37034 injection [1] - China National Pharmaceutical Group (01177) had the application for the new indication of Kumosil capsules for first-line treatment of breast cancer accepted [1] - Oceanwide Holdings (08476) applied to the Stock Exchange for a transfer listing to the main board [1] Financial Data - Kaison Holdings (00102) reported a loss attributable to shareholders of approximately HKD 740 million for 2023, a shift from profit to loss year-on-year [1] - JiaoGe Friends Holdings (01450) achieved a cumulative GMV of approximately CNY 6.98 billion in the first half of the year, a year-on-year increase of approximately 17.11% [1] - Sunny Optical Technology (02382) reported a smartphone lens shipment of approximately 95.056 million units in June, a month-on-month decrease of 3.1% and a year-on-year decrease of 12.7% [1] - Fast Retailing (06288) announced a profit attributable to the parent company of JPY 339.099 billion for the first three quarters, a year-on-year increase of 8.4% [1] - Jianye Real Estate (00832) reported a total property contract sales of CNY 4.44 billion in the first half of the year, a year-on-year decrease of 1.2% [1] - China Lilang (01234) reported a mid-to-high single-digit year-on-year growth in retail sales of "LILANZ" products in the first half of the year [1]

联邦制药公告，公司全资附属公司联邦生物科技(珠海横琴)有限公司研发的1类创新药UBT37034注射液 获美国食品药品监督管理局(FDA)批准，IND编号为175188。该药物适用于超重或肥胖适应症，是一款 新型多肽类受体激动剂，可通过选择性作用于神经肽Y2受体减轻体重。临床前多种动物模型研究结果 显示，UBT37034与GLP-1类似物联用能够显著降低体重。未来，公司将持续致力于新产品研发，提升 在生物医药行业的竞争力及创造力，预期将为公司及其股东创造更大收益。 ...

华夏时报（www.chinatimes.net.cn）记者 于娜 见习记者 赵文娟 北京报道 南京维立志博生物科技股份有限公司（下称"维立志博"）再度向港交所递交招股书，谋求主板上市，摩根士丹利 与中信证券担任联席保荐人。作为一家深耕肿瘤、自身免疫性疾病等领域的临床阶段生物药企，维立志博成立以 来备受资本青睐，8轮融资募集约10.84亿元，恩然创投、汉康资本、正心谷资本等明星机构纷纷入局，IPO前的最 后一轮融资，维立志博投后估值已达31.3亿元。 光鲜的融资履历背后，维立志博的经营困境也逐渐显露。核心产品商业化前景不明，唯一授权协议终止致收入归 零，2023年至2025年第一季度超7亿元的累计亏损，叠加现金流持续为负、资不抵债的财务压力，都让此次IPO面 临重重考验。 | | 天使輸融資 | Pre-A 輸 融資 | A 輪 程 資 | A+輸盈资 | B輸盈资 | B+輸盈資 | C輸盈资 | C+輪麗資 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 倍擴日期 | 2015年7月10日 | 2017年6月16日 | 2018年8月2 ...

智通财经APP获悉，据港交所6月17日披露，岸迈生物科技有限公司向港交所主板递交上市申请，中信证券和招银国际为联席保荐人。 据招股书，岸迈生物是一家处于临床阶段的生物技术公司，处于双特异性抗体治疗领域的创新前沿，专注于在全球范围内开发治疗各类癌症和自身免疫性疾 病的T细胞衔接器。 岸迈生物的肿瘤学业务管线包括三款处于临床阶段的候选药物，包括(i)核心产品EMB-01(靶向EGFR/cMET)，用于治疗结直肠癌，(ii)两款基于T细胞衔接器 的关键产品EMB-06(靶向BCMA/CD3)，用于治疗多发性骨髓瘤("MM")和EMB-07(靶向ROR1/CD3)，用于治疗淋巴瘤及实体瘤，及(iii)三款基于T细胞衔接器 的临床前候选药物EM1032(靶向ALPP(G)/CD3)、EM1034(靶向LY6G6D/CD3)和EM1031(靶向 KLK2/CD3)。岸迈生物的免疫学业务管线包括一款处于临床阶 段的候选药物，即基于T细胞衔接器的关键产品EMB-06，以及两款基于T细胞衔接器的临床前候选药物EM1039和EM1042。 战略合作上，根据弗若斯特沙利文的资料，自2023年底起，岸迈生物已建立多个全球对外授权合作 ...